Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images. (July 2022)

• Record Type: Journal Article
• Authors: Wang, Ching-Wei; Chang, Cheng-Chang; Lee, Yu-Ching; Lin, Yi-Jia; Lo, Shih-Chang; Hsu, Po-Chao; Liou, Yi-An; Wang, Chih-Hung; Chao, Tai-Kuang
• Is Part Of: Computerized medical imaging and graphics. Volume 99(2022)
• Publication Date: 2022-07
• Subjects: Epithelial ovarian cancer -- Precision Oncology -- Weakly supervised deep learningframework -- Whole-slide image analysis -- Histopathological Images; Diagnostic imaging -- Periodicals; Imaging systems in medicine -- Periodicals; Diagnosis, Radioscopic -- Data processing -- Periodicals; Diagnostic Imaging -- Periodicals; Imagerie pour le diagnostic -- Périodiques; Diagnostic imaging; Periodicals; Electronic journals; Electronic journals; 616.0754
• DOI: 10.1016/j.compmedimag.2022.102093
• Languages: English
• ISSNs: 0895-6111

Abstract

Abstract: Despite the progress made during the last two decades in the surgery and chemotherapy of ovarian cancer, more than 70 % of advanced patients are with recurrent cancer and decease. Surgical debulking of tumors following chemotherapy is the conventional treatment for advanced carcinoma, but patients with such treatment remain at great risk for recurrence and developing drug resistance, and only about 30 % of the women affected will be cured. Bevacizumab is a humanized monoclonal antibody, which blocks VEGF signaling in cancer, inhibits angiogenesis and causes tumor shrinkage, and has been recently approved by FDA as a monotherapy for advanced ovarian cancer in combination with chemotherapy. Considering the cost, potential toxicity, and finding that only a portion of patients will benefit from these drugs, the identification of new predictive method for the treatment of ovarian cancer remains an urgent unmet medical need. In this study, we develop weakly supervised deep learning approaches to accurately predict therapeutic effect for bevacizumab of ovarian cancer patients from histopathological hematoxylin and eosin stained whole slide images, without any pathologist-provided locally annotated regions . To the authors' best knowledge, this is the first model demonstrated to be effective for prediction of the therapeutic effect of patients with epithelial ovarian cancer to bevacizumab. Quantitative evaluation of a whole section dataset shows that the proposed method achieves high accuracy, 0.882 ± 0.06; precision, 0.921 ± 0.04, recall, 0.912 ± 0.03; F-measure, 0.917 ± 0.07 using 5-fold cross validation and outperforms two state-of-the art deep learning approaches Coudray et al. (2018), Campanella et al. (2019) . For an independent TMA testing set, the three proposed methods obtain promising results with high recall (sensitivity) 0.946, 0.893 and 0.964, respectively. The results suggest that the proposed method could be useful for guiding treatment by assisting in filtering out patients without positive therapeutic response to suffer from further treatments while keeping patients with positive response in the treatment process. Furthermore, according to the statistical analysis of the Cox Proportional Hazards Model, patients who were predicted to be invalid by the proposed model had a very high risk of cancer recurrence (hazard ratio = 13.727) than patients predicted to be effective with statistical signifcance ( p < 0.05). Graphical Abstract: ga1 Highlights: The first automatic effective indicator for treatment effectiveness of ovarian cancer based on histopathological data. A hybrid deep learning classification framework. A weakly supervised deep learning segmentation framework. Save medical resources and save patients from unnecessary treatment. Efficient gigapixel WSI analysis within two minutes. A precision oncology model for ovarian cancer.